Marianna Nuti

Pubblicazioni

Titolo Pubblicato in Anno
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line JOURNAL OF TRANSLATIONAL MEDICINE 2024
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma IMMUNITY 2024
Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 2024
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach CANCER IMMUNOLOGY, IMMUNOTHERAPY 2023
Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2023
Membrane and Soluble CD137 in Systemic Lupus Erythematosus: Role as Biomarkers for Disease Activity JOURNAL OF IMMUNOLOGY RESEARCH 2023
Macrophage galactose-like lectin mediated interactions: investigating immunosuppressive mechanisms in glioblastoma www.siica.it 2023
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors FRONTIERS IN IMMUNOLOGY 2023
Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs JOURNAL OF TRANSLATIONAL MEDICINE 2023
Circulating CD137+ T cell subsets and MDCSs as immune biomarkers for response to anti-PD1 immunotherapy in NSCLC patients AICC INTERNATIONAL MEETING – TRANSLATIONAL AND PRECISION MEDICINE 2023
Circulating CD137 + T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients CLINICAL CANCER RESEARCH 2022
Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study HUMAN VACCINES & IMMUNOTHERAPEUTICS 2022
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response EBIOMEDICINE 2022
Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2022
Human duodenal submucosal glands contain a defined stem/progenitor subpopulation with liver-specific regenerative potential JOURNAL OF HEPATOLOGY 2022
Soluble PD-L1 as a prognostic factor for Immunotherapy treatment in solid tumors: Systematic review and Meta-Analysis INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 2022
Genomic and immune approach in platinum refractory HPV-negative head and neck squamous cell carcinoma patients treated with Immunotherapy: a novel combined profile BIOMEDICINES 2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy FRONTIERS IN IMMUNOLOGY 2022
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients ANNALS OF ONCOLOGY 2022
CD137+ T-Cells: Protagonists of the immunotherapy revolution CANCERS 2021

ERC

  • LS2_15
  • LS4_6
  • LS4_12
  • LS6
  • LS6_3
  • LS6_10
  • LS7_2

KET

  • Life-science technologies & biotechnologies

Interessi di ricerca

Precision Medicine with particular interest in tumor immunology and the identification of mechanisms involved in the tumor- immunity interaction. Development of strategies for the activation of immunity in cancer patients and reduction of immunosuppression. Identification of biomarkers in immunity. Identification and study of the Interactions of drugs and targeted therapy with the immune systems of cancer patiemts. Immunotherapy clinical trials.

Keywords

tumor immunology
precision medicine
anticancer immunotherapy
Cancer vaccines

Progetti di Ricerca

Laboratori di ricerca

Immunologia dei tumori

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma